QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 jmp-securities-maintains-market-outperform-on-iovance-biotherapeutics-lowers-price-target-to-23

JMP Securities analyst Reni Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and lowers the...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 whats-going-on-with-iovance-biotherapeutics-today

On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for fro...

 reported-earlier-iovance-to-present-updated-clinical-data-for-lifileucel-in-combination-with-pembrolizumab-in-frontline-advanced-melanoma-at-asco-annual-meeting

Response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïv...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 iovance-biotherapeutics-q1-2024-gaap-eps-042-inline-sales-715000k-miss-2075m-estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. ...

 ahn-cancer-institute-to-offer-groundbreaking-treatment-for-metastatic-melanoma-the-one-time-treatment-made-by-iovance-biotherapeutics-is-the-first-fda-approved-t-cell-therapy-for-solid-tumors

Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a firs...

 piper-sandler-maintains-overweight-on-iovance-biotherapeutics-raises-price-target-to-19

Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the pric...